Crenezumab
Crenezumab (pronunciation: kreh-NEZ-oo-mab) is a monoclonal antibody designed for the treatment of Alzheimer's disease. It was developed by the Swiss pharmaceutical company AC Immune and licensed to Genentech, a member of the Roche Group.
Etymology
The name "Crenezumab" is derived from the Latin word "crenatus," meaning "notched," and "zumab," a common suffix for humanized monoclonal antibodies.
Mechanism of Action
Crenezumab works by binding to amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. This binding is thought to prevent the formation of these plaques and potentially remove existing ones, thereby slowing the progression of the disease.
Clinical Trials
Crenezumab has been tested in several clinical trials, including a large Phase III trial. However, in 2019, it was announced that the drug did not meet its primary endpoints in this trial, and development was discontinued.
Related Terms
External links
- Medical encyclopedia article on Crenezumab
- Wikipedia's article - Crenezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski